Weight loss with glucagon‐like peptide‐1 receptor agonists in <scp>Bardet‐Biedl</scp> syndrome
Shawg Ganawa, Smrithi Hema Santhosh, Lucy J. Parry, Akheel A. Syed
Abstract
Bardet-Biedl syndrome (BBS) is a rare genetic condition, characterized by ciliary protein dysfunction, leading to multi-organ damage. People with BBS can develop early-onset severe obesity and associated problems including the metabolic syndrome, type 2 diabetes and coronary heart disease. Weight management can be challenging with the lack of effective medical therapies so far. We report a patient with BBS who underwent successful weight reduction through the use of glucagon-like peptide-1 receptor agonists.
Topics & Concepts
Bardet–Biedl syndromeMedicineObesityMetabolic syndromeWeight lossInternal medicineEndocrinologyReceptorType 2 diabetesDiabetes mellitusBioinformaticsGeneticsGenePhenotypeBiologyGenetic and Kidney Cyst DiseasesGenetic Syndromes and ImprintingHedgehog Signaling Pathway Studies